About Lung Cancer Liquid Biopsy
A liquid biopsy helps to identify free-floating tumor DNA (also known as circulating DNA) within the blood sample of a patient. Lung cancer liquid biopsy helps to detect the epidermal growth factor receptor (EGFR) mutation and other identified mutations, which are responsible for lung cancer. It is observed that the use of a liquid biopsy to identify carcinogenic cells of lungs will help in the early diagnosis of lung cancer.
Technavio’s analysts forecast the global lung cancer liquid biopsy market to grow at a CAGR of 17.15% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global lung cancer liquid biopsy market for 2017-2021. To calculate the market size, the report considers the sales and values of lung cancer liquid biopsy assays.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Lung Cancer Liquid Biopsy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Biocept
• Exosome Diagnostics
• F. Hoffmann-La Roche
• QIAGEN
Other prominent vendors
• AccuraGen
• Agena Bioscience
• BARD1
• BGI
• Biodesix
• Bio-Rad Laboratories
• Cancer Genetics
• CellMax Life
• Circulogene
• CLEARBRIDGE BIOMEDICS
• Cynvenio Biosystems
• EntroGen
• Epic Sciences
• Epigenomics
• Fluxion Biosciences
• Freenome
• Gencurix
• Genetracer Biotech
• Genomic Health
• Grail
• Guardant Health
• HeliTec
• Inivata
• Lonza
• MedGenome
• Nanoview Diagnostics
• Natera
• Novogene
• OncoCyte
• OncoDNA
• Pathway Genomics
• Personal Genome Diagnostics
• Predicine
• Shuwen Biotech
• Sysmex
• Thermo Fisher Scientific
• Transgenomic
• Trovagene
Market driver
• Rising incidence of lung cancer
• For a full, detailed list, view our report
Market challenge
• High cost of lab testing procedure
• For a full, detailed list, view our report
Market trend
• Vendors' focus on clinical trials
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
• Market outline
PART 05: MARKET LANDSCAPE
• Market ecosystem
• Market segmentation analysis
PART 06: MARKET SIZING
• Market definition
• Market sizing 2016
• Market size and forecast 2016-2021
PART 07: FIVE FORCES ANALYSIS
PART 08: MARKET SEGMENTATION BY PRODUCT
• Segmentation by product
• Comparison by product
• Global lung cancer liquid biopsy market by CTCs and ctDNA
• Global lung cancer liquid biopsy market by exosomes and RNA
• Market opportunity by product
PART 09: MARKET SEGMENTATION BY END-USER
• Segmentation by end-user
• Market share by end-user
• Clinical diagnostic laboratories
• Hospitals and clinics
• Physicians' office laboratories
PART 10: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Lung cancer liquid biopsy market in Americas
• Lung cancer liquid biopsy market in EMEA
• Lung cancer liquid biopsy market in APAC
• Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 13: MARKET TRENDS
• Growing partnership agreements
• Vendors' focus on clinical trials
• Application of liquid biopsy for personalized treatment
PART 14: VENDOR LANDSCAPE
• Competitive landscape
PART 15: KEY VENDOR ANALYSIS
• Biocept
• Exosome Diagnostics
• F. Hoffmann-La Roche
• QIAGEN
• Key companies to watch
• Other prominent vendors
PART 16: APPENDIX
• List of abbreviations
List of Exhibits
Exhibit 01: Overview of tissue biopsy and liquid biopsy used for detection of lung cancer
Exhibit 02: Parent market
Exhibit 03: Market segments
Exhibit 04: Market size 2016
Exhibit 05: Global lung cancer liquid biopsy market 2016-2021 ($ millions)
Exhibit 06: Global lung cancer liquid biopsy market: Year-over-year growth 2017-2021 (%)
Exhibit 07: Five forces analysis
Exhibit 08: Global lung cancer liquid biopsy market by product 2016-2021 (%)
Exhibit 09: Comparison by product
Exhibit 10: Global lung cancer liquid biopsy market by CTCs and ctDNA: Market overview
Exhibit 11: Global lung cancer liquid biopsy market by CTCs and ctDNA 2016-2021 ($ millions)
Exhibit 12: Global lung cancer liquid biopsy market by CTCs and ctDNA: Year-over-year growth 2017-2021 (%)
Exhibit 13: Global lung cancer liquid biopsy market by exosomes and RNA: Market overview
Exhibit 14: Global lung cancer liquid biopsy market by exosomes and RNA 2016-2021 ($ millions)
Exhibit 15: Global lung cancer liquid biopsy market by exosomes and RNA: Year-over-year growth 2017-2021 (%)
Exhibit 16: Market opportunity by product
Exhibit 17: Market share by end-user
Exhibit 18: Global lung cancer liquid biopsy market by end-users 2016: Market overview
Exhibit 19: Global lung cancer liquid biopsy market by geography 2016-2021 (%)
Exhibit 20: Regional comparison
Exhibit 21: Lung cancer liquid biopsy market in Americas 2016-2021 ($ millions)
Exhibit 22: Lung cancer liquid biopsy market in Americas: Year-over-year growth 2017-2021 (%)
Exhibit 23: Top 3 countries in Americas
Exhibit 24: Lung cancer liquid biopsy market in EMEA 2016-2021 ($ millions)
Exhibit 25: Lung cancer liquid biopsy market in EMEA: Year-over-year growth 2017-2021 (%)
Exhibit 26: Top 3 countries in EMEA
Exhibit 27: Lung cancer liquid biopsy market in APAC 2016-2021 ($ millions)
Exhibit 28: Lung cancer liquid biopsy market in APAC: Year-over-year growth 2017-2021 (%)
Exhibit 29: Top 3 countries in APAC
Exhibit 30: Addressable market of lung cancer 2016
Exhibit 31: Limitations associated with the application of lung cancer liquid biopsy
Exhibit 32: Competitive structure analysis of global lung cancer liquid biopsy market 2016
Exhibit 33: Strategic success factors of companies in global lung cancer liquid biopsy market 2016
Exhibit 34: Biocept: Key highlights
Exhibit 35: Biocept: Strength assessment
Exhibit 36: Biocept: Strategy assessment
Exhibit 37: Biocept: Opportunity assessment
Exhibit 38: Exosome Diagnostics: Key highlights
Exhibit 39: Exosome Diagnostics: Strength assessment
Exhibit 40: Exosome Diagnostics: Strategy assessment
Exhibit 41: Exosome Diagnostics: Opportunity assessment
Exhibit 42: F. Hoffmann-La Roche: Key highlights
Exhibit 43: F. Hoffmann-La Roche: Strength assessment
Exhibit 44: F. Hoffmann-La Roche: Strategy assessment
Exhibit 45: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 46: QIAGEN: Key highlights
Exhibit 47: QIAGEN: Strength assessment
Exhibit 48: QIAGEN: Strategy assessment
Exhibit 49: QIAGEN: Opportunity assessment
Exhibit 50: Biocartis: Company assessment
Exhibit 51: Siemens Healthcare: Company assessment
Exhibit 52: Global lung cancer liquid biopsy market: Other prominent vendors
